- Oncology Drug Reference Sheet: Tislelizumab-Jsgr - ons. org
Tislelizumab-jsgr (Tevimbra®) is a programmed cell death protein-1 (PD-1) blocking antibody approved in the United States in 2024 for the treatment of certain esophageal and gastric cancers It is administered via IV and works by enhancing the immune system’s ability to target cancer cells
- Drugs Approved for Esophageal Cancer - NCI
This page lists cancer drugs approved by the Food and Drug Administration (FDA) for esophageal cancer, including gastroesophageal junction cancer The list includes generic names and brand names
- Tislelizumab Uses, Side Effects Warnings - Drugs. com
What is tislelizumab? Tislelizumab is used in adults to treat cancer of esophagus that has spread to other parts of the body (metastatic) or cannot be removed with surgery Your doctor will make sure you have correct tumor type to be treated with tislelizumab Tislelizumab may also be used for purposes not listed in this medication guide
- ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer) TEVIMBRA may be used in combination with chemotherapy that contains platinum as your first treatment when your esophageal cancer: is a type called squamous cell carcinoma, and cannot be removed with surgery or has spread to other parts of the body
- Tislelizumab: Side Effects, Uses, Dosage, Interactions, Warnings
Tislelizumab is a prescription medication indicated for: Esophageal Cancer In combination with platinum-containing chemotherapy as first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death- (Ligand) 1 [PD- (L)1] (greater than or equal to 1) As a single agent in adults with unresectable or metastatic ESCC
- New Treatment Strategies for Esophageal Cancer | Blog | AACR
A study published in the AACR journal Clinical Cancer Research in November 2024 showed that adding tislelizumab to standard-of-care chemotherapy and radiation shrank unresectable esophageal tumors enough to make them eligible for surgical resection, which, in turn, led to longer patient survival
- Comparative Efficacy and Safety of Tislelizumab in Second . . .
Introduction Esophageal squamous cell carcinoma (ESCC) accounts for approximately 90% of all esophageal cancer cases and is associated with poor prognosis However, recent advancements have transformed the treatment landscape Tislelizumab, a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (PD-1) monoclonal antibody, was developed to overcome resistance mechanisms by
- Tislelizumab Approved for Advanced, Metastatic Esophageal . . .
Dr Kim provides an overview of the FDA approval of tislelizumab for the treatment of advanced, metastatic esophageal cancer
- ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr) | HCPs
Esophageal Cancer In combination with platinum-containing chemotherapy for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1)
- Kato Breaks Down FDA Approval of Tislelizumab in Esophageal . . .
Ken Kato, MD, discussed the FDA approval of tislelizumab for the first-line treatment of esophageal squamous cell carcinoma On March 4, 2025, the FDA approved the combination of tislelizumab-jsg r (Tevimbra) and platinum-containing chemotherapy as a frontline treatment for adult patients with
|